PUBLIC COMPANY
save$EXELEXELIXIS, INC.
$EXEL58.80+0.67%Alameda, CA, USupdated 1d ago
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
community read0 votes
pipeline
8
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(8)
pipeline depth8 products
4Phase 11Phase 31Marketed1pre_registration1Unknown
Marketed
cabozantinib s-malate
Endometrial Cancer
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
Phase 3CABOMETYX
1 INDICATIONS AND USAGE CABOMETYX is a kinase inhibitor i…
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
Phase 1XB-010
Endometrial Cancer
Phase 1XB-371
Solid Tumor
Phase 1XB-628
Solid Tumor
Phase 1XL-309
Fallopian Tube Cancer
drugCOMETRIQ
1 INDICATIONS AND USAGE COMETRIQ is indicated for the tre…
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
pre_registrationzanzalintinib fumarate
Metastatic Colorectal Cancer
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
next earnings Oct 27, 2026
News
- Out of sight, out of work? What’s driving remote job cutsBiopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis.biospace · 1mo ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that